A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

NCT04494243 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG: AD-214 10/600mg
DRUG: Rabeprazole 10mg

Sponsor

Addpharma Inc.